A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects

NCT05099133 | Completed Phase 1 FDA Drug

• 1 other identifier: LP0145-1486
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This trial will investigate the pharmacokinetics, immunogenicity, safety, and tolerability of LEO 138559 in healthy Japanese subjects. The trial consists of a screening period of up to 4 weeks, a single treatment with either LEO 138559 or placebo, and 8 follow-up visits to Day 85. A total of 24 healthy subjects will be enrolled in 3 dose groups (n=8 per dose group) and randomized to either LEO 138559 or placebo in a ratio of 6:2.

Conditions

Atopic Dermatitis

Outcome Measures

Primary Outcomes (7)

• AUC0-last: the area under the concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• AUC0-inf: area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• Cmax: maximum serum LEO 138559 concentration

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• tmax: time of maximum serum LEO 138559 concentration

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• t½: terminal elimination half-life

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• CL/F: apparent total body clearance

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

• Vz/F: apparent volume of distribution

  Pharmacokinetic endpoint to be determined from serum concentrations

  From Day 1 to Day 85

Secondary Outcomes (2)

• Number of treatment emergent adverse events

  From Day 1 to Day 85

• Presence of binding anti-drug antibodies

  Day 1(pre-dose), Day 29, Day 57, and Day 85

Study Arms (4)

LEO 138559 Dose 1

EXPERIMENTAL

LEO 138559 will be administered subcutaneously up to 3 injections per dosing

Drug: LEO 138559

LEO 138559 Dose 2

EXPERIMENTAL

LEO 138559 will be administered subcutaneously up to 3 injections per dosing

Drug: LEO 138559

LEO 138559 Dose 3

EXPERIMENTAL

LEO 138559 will be administered subcutaneously up to 3 injections per dosing

Drug: LEO 138559

Placebo

PLACEBO COMPARATOR

LEO 138559 placebo will be administered subcutaneously up to 3 injections per dosing

Drug: LEO 138559 Placebo

Interventions

LEO 138559 DRUG

LEO 138559 is an antibody given by injection just under the skin.

LEO 138559 Dose 1; LEO 138559 Dose 2; LEO 138559 Dose 3

LEO 138559 Placebo DRUG

LEO 138559 placebo is given by injection just under the skin. LEO 138559 placebo contains the same excipients in the same concentration as LEO 138559, except the medical ingredient LEO 138559.

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females between 18 to 65 years of age, inclusive, at the Screening visit
• Japanese subjects to be considered ethnic Japanese must:
• Be born in Japan with parents and grandparents (maternal and paternal) of Japanese descent
• Not have lived outside of Japan for more than 10 years at the time of Screening
• No significant change in lifestyle since leaving Japan, including diet.
• Body mass index (BMI) between 18.0 and 32.0 kg/m2, inclusive, at the Screening visit.
• Healthy, determined by pre-trial medical evaluation at Principal Investigator's discretion

You may not qualify if:

• Female subjects of childbearing potential who are not willing to use highly effective contraception.
• Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, immunological, musculoskeletal, infectious, metabolic, hematologic, neurological, or psychiatric disorder(s) as determined by the Principal Investigator or designee.
• Subject has any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of any drug as determined by the Principal Investigator or designee.
• Clinically significant infection within 4 weeks prior to randomization that may compromise the safety of the subject in the trial or the integrity of the trial. This includes clinically significant infections (common cold is allowed \[with negative SARS-CoV-2 PCR test\]) that in the opinion of the Investigator or Sponsor's Medical Monitor may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject's ability to participate in the trial.
• History of any active skin infection within 1 week prior to Screening or randomization.
• Subject who has taken immunosuppressive/immunomodulating medication within 4 weeks prior to randomization, topical corticosteroids, topical calcineurin inhibitors within 2 weeks prior to randomization, or was treated with biologics within 5 half-lives (if known) or 12 weeks prior to randomization, whichever is longer.
• Subject has used over-the-counter (OTC) medications (including vitamins), or herbal remedies from 14 days prior to admission until the End-of-trial Visit. By exception, paracetamol/acetaminophen ≤ 2 g per day is permitted.
• History of chronic alcohol or drug abuse within 12 months prior to Screening, or any condition associated with poor compliance as judged by the Investigator.
• Heavy smoker (daily average \>10 cigarettes) within the last three months prior to Screening.
• Subject is unwilling to avoid use of alcohol or alcohol-containing foods, medications, or beverages, within 36 hours prior to admission until discharge from the Clinical Unit.
• Female subjects are breastfeeding or female subjects with a positive serum pregnancy test at the Screening visit or urine pregnancy test at admission.
• Subject is unwilling to avoid consumption of coffee and caffeine-containing beverages within 48 hours prior to admission until discharge from the Clinical Unit.
• Subject is unable to abstain from smoking (or other nicotine use) from admission until discharge from the Clinical Unit.
• Subject scheduled to receive COVID-19 vaccination within 2 weeks before IMP administration.
• Less than 4 weeks after the second COVID-19 vaccination or booster (if on a single dose vaccination, it should be 4 weeks after).

Sponsors & Collaborators

• LEO Pharma: lead

Study Sites (1)

LEO Investigational Site

Los Angeles, California, 91206, United States

Location

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• Medical Expert

  LEO Pharma

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 18, 2021
• First Posted: October 29, 2021
• Study Start: November 3, 2021
• Primary Completion: June 28, 2022
• Study Completion: June 28, 2022
• Last Updated: February 24, 2025

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)